Guías de Práctica Clínica en Pediatría

152

a barredores de radicales libres como la superóxido dismutasa humana recombinante y a

inhibidores de la PDE-1 como el zaprinast.

BIBLIOGRAFÍA

1. Porta N, Steinhorn R. Pulmonary Vasodilator Therapy in the NICU : Inhaled Nitric Oxide, Sildenafil

and other Pulmonary Vasodilating Agents. Clin Perinatol 2012; 39: 149-64.

2. Kondury G, KimO.Advances in the Diagnosis andManagement of Persistent Pulmonary Hypertension

of the Newborn. Pediatr Clin N Am 2009; 56: 579-600.

3. Dhillon R. The Management of Neonatal Pulmonary Hypertension. Arch Dis Child Fetal Neonatal Ed

2012; 97: F223-F8.

4. Farrow K, Steinhorn R. Phosphodiesterases: Emerging Therapeutic Targets for Neonatal Pulmonary

Hypertension. Handb Exp Pharmacol 2011; 204: 251-77.

5. Noori S, Seri I. Neonatal Blood Pressure Support: The Use of Inotropes, Lusitropes and other

Vasopressor Agents. Clin Perinatol 2012; 39: 221-38.